Anoikis is a unique mode of apoptotic cell death that occurs consequentially to insufficient
cell-matrix interactions. Resistance to anoikis is a critical contributor to tumor invasion and …

Androgens promote the growth and differentiation of prostate cells through ligand activation
of the androgen receptor (AR). Sensitization of the androgenic response by multifunctional …

Prostate cancer progression requires active androgen receptor (AR) signaling which occurs
following translocation of AR from the cytoplasm to the nucleus. Chemotherapy with taxanes …

Recent insights into the regulation of the androgen receptor (AR) activity led to novel
therapeutic targeting of AR function in prostate cancer patients. Docetaxel is an approved …

Prostate specific membrane antigen (PSMA) is a validated molecular marker for prostate
cancer. A series of glutamate− urea (Glu-urea-X) heterodimeric inhibitors of PSMA were …

Androgens are functionally required for the normal growth of the prostate gland and in
prostate tumor development and progression. Epithelial-mesenchymal-transition (EMT) is an …

Abstract Background [177 Lu] Lu-PSMA-617 is a well-tolerated therapy for the treatment of
metastatic prostate cancer. However, because of the mainly renal excretion of the tracer, the …

Anoikis is a mode of apoptotic cell death, consequential to insufficient cell–matrix
interactions and a critical player in tumor angiogenesis and metastasis. The events involved …

Prostate cancer is the most common noncutaneous malignancy affecting men in North
America. Radical prostatectomy remains a definitive treatment for prostate cancer. However …

Prostate-specific membrane antigen (PSMA) is a cell membrane glycoprotein that is
selectively expressed in prostate cells, with expression levels increasing dramatically in …